00
0LGMD Awareness Day Dare to bust a move challenge.
Wednesday 22 July 2015
Tuesday 14 July 2015
Muscle exercise in limb girdle muscular dystrophies: pitfall and advantages
This infomation has not been altered in anyway and is meant to provide information to all living with LGMD. This is the original version as it appears in: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478773/
Introduction
In limb girdle muscular dystrophies (LGMD), different genetic mutations, through distinct pathogenic mechanisms, determine a failure of muscle fibers in maintaining their physical structure during contraction, leading to sarcolemma breakdown, progressive muscle fibers degeneration and strength loss. Depending on that, exercise tolerance is affected in patients with LGMD, either as a direct consequence of loss of muscle fibers, but also secondary to the sedentary lifestyle due to the motor impairment. However, the cellular mechanisms that triggers skeletal muscle dysfunction and, ultimately, leads to muscle necrosis is still unclear, and available therapies are consequently inadequate.
Pathophysiology of fatigue and exercise intolerance in muscular dystrophies
Muscular dystrophies are genetic muscle diseases characterized by a progressive loss of motor unit constituents, due to different degeneration mechanisms, and by a wide range of phenotypes. Like dystrophinopathies (Duchenne and Becker muscular dystrophy, DMD, BMD), the majority of LGMD, that result from mutations in genes encoding specific structural protein, are prototypes of failure of the muscle fiber to maintain its physical structure during contraction, leading to sarcolemma breakdown, myofiber degeneration and necrosis.
As a consequence, more than 60% of dystrophic patients experiences severe fatigue as a common and precocious symptom of disease manifestation. Muscle fatigue occurs when the intended physical activity can no longer be continued or is perceived as excessive effort and discomfort, depending on the interaction between the required force, the maximum force that the myofiber produces, as well as its endurance, also defined as fatigue resistance. At molecular level, although the loss of skeletal muscle mass accompanying the dystrophic process may be considered as a pathogenic factor in reduced muscle force generation in LGMD, several other and often interconnected mechanisms, as excitationcontraction coupling or energy breakdown, are involved in the genesis of muscle fatigue. However, the exact mechanism of the progressive muscle fibers necrosis in muscular dystrophies is still unknown, as well as the role of energy production in the cascade of events ending with muscle fiber degeneration. Related to that, evidence that the tricarboxylic acid cycle and some reactions in glycolysis are dependent on the integrity of cytoskeletal organization may suggest a role for defective energy metabolism in muscle fiber degeneration. In the clinical setting, a careful analysis of the muscle function is important to characterize the "phenomic" of muscle force impairment and fatigue in muscular dystrophies and to design outcome measures and optimal strategies to treat patients with decreased fatigue resistance (1).
A better knowledge of the muscle metabolic changes during exercise may be useful in understanding the role energy utilization plays in contractile insufficiency and pathogenic mechanisms. For these purposes, 31Phosphorus (31P) magnetic resonance spectroscopy (MRS) may be used to study skeletal muscle metabolismin vivo. The technique has become an important tool in the study of the pathophysiology of muscle diseases. 31P-MRS is used for providing information about the biochemical composition and metabolism of tissue without invasive sampling, and it has the unique ability to measure intracellular pH. Given that MRS is well tolerated and examinations are easily repeated, it may also be applied in longitudinal studies of disease progression or outcomes. Interestingly, studies performed by muscle 31P-MRS have shown significant differences in several metabolite ratios in dystrophic patients indicating a lower energy state (2). In particular, the reduced cytosolic acidification during exercise suggests a defective glycolytic activity in skeletal muscle of patients with Becker muscular dystrophy. A recent work performed by our group studied the exercise-related muscle metabolism in mildly affected BMD patients assessed by muscle 31P-MRS during an incremental workload. We observed that BMD patients, compared with normal controls, showed downregulation of resting pH and intramuscular membrane breakdown, an increased anaerobic metabolism during sustained submaximal contraction and the maintenance of oxidative function during recovery (3).
Lodi and coworkes in 1997 (4) used MR imaging and 31P-MRS to study skeletal muscle in seven patients with LGMD with a variable deficiency of the alpha- (D), beta- (E), and gamma- (C) sarcoglycan but normal dystrophin expression on muscle biopsy. In LGMD patients, the authors observed that calf muscle phosphorylated compound content did not differ from controls, but the cytosolic pH was increased. Notably, the degree of calf muscle fat replacement inversely correlatedwith cytosolic pH and directly with phosphocreatin/adenosine triphosphate (PCr/ATP). Muscle oxidative metabolism was normal in LGMD2-C,- D,-E patients. The authors concluded that primary deficits of sarcoglycan complex lead to specific morphological and metabolic patterns of skeletal muscle involvement. In a recent study, we assessed exercise-related muscle metabolism by muscle 31P-MRS during an incremental workload in 10 mildly affected LGMD2A (6 males, 4 females, mean age 31.4 ± 9.5) patients and 3 LGMD2B patients, and 20 healthy controls (unpublished data). The incremental workload exercise test consisted of isometric intermittent plantar flexions of the dominant leg through an MR-compatible ergometer. Test normalization was obtained with reference to individual isometric maximal voluntary contraction (MVC), a valuable force indicator in contracting muscles. The inmagnet exercise protocol was made up of an incremental workload starting from 20% of the mean MVC (re-measured at rest 1 hour before the examination) and progressively increased by 10% MVC every 30 seconds until the subject's exhaustion (3). 31P MRS data were acquired from calf muscles. At rest, LGMD-2A and -2B subjects had a significantly higher cytosolic pH (p < 0.03), an increase in phosphodiesters (PDE), as markers of membrane rupture, and adenosine diphosphate (ADP) (p < 0.02), while they showed a reduction of phosphocreatine (PCr) (p < 0.01) compared with controls. No significant differences were found in mean values of metabolic variables during exercise between LGMD subjects and controls, while, at the end of exercise, PCr recovery rate in PGMD2A was significantly reduced (p < 0.02) in comparison with LGMD2B subjects and healthy controls, suggesting an alteration of oxidative metabolism.
However, when considering metabolic pathway related to fatigue in muscular dystrophies, reports have shown that lactic acid does not have always a deleterious influence on muscle contraction and it does not cause muscle fatigue. In fact, althought the reduced intracellular pH may alter muscle performance, given that the glycogen storage is more rapidly depleted when consumed anaerobically, producing lactic acid, it is also likely that its deleterious effects have been overestimated (5).
Alternatively, it has been proposed that the effects of ionic changes, i.e. the changes in the homeostasis of Ca2+ and reactive oxygen species (ROS) in the myoplasm, cause muscle fatigue.
Failure in calcium release is one of the major contributor to fatigue. Sarcoplasmic reticulum (SR) Ca2+ stores decline during fatigue. It has been demonstrated that the increased inorganic phosphate (Pi) affect fatigue development by acting on SR Ca2+ handling, by reducing cross-bridge force and the Ca2+ sensitivity of the myofilaments, with secondary early drop in force (1). According to the "Ca2+ precipitation theory", if Pi goes into the SR during fatigue, this can result in Ca-Pi precipitation and decrease of the Ca2+ available for release.
There is also a growing literature that indicates the "oxidative stress" as major source of signal pathway in the generation of muscle fatigue (6, 7). The superoxide anion (O2•–) is one of the major reactive oxygen species (ROS). In addition, O2•– reacts with nitrogen oxide (NO), with the production of peroxynitrite (ONOO–), a reactive nitrogen species (RNS). Muscle contraction requires a large amount of ATP. The majority of ATP is produced by mitochondrial oxidative phosphorylation (OXPHOS); during exercise, mitochondria utilize an amount of O2 which is up to 100-fold higher than the one used during resting. The high rate of O2 consumption in skeletal muscles determines also an electron dispersion from the electron transfer chain during OXPHOS, with secondary generation of O2•– (8). ROS/RNS production in muscles causes oxidative stress that is dangerous for cellular DNA, proteins and lipids. ROS have been identified as endogenous mediators of muscle fatigue, highlighting the importance to develop antioxidants as therapeutic interventions for fatigue treatment (8).
The nitric oxide (NO) pathway has also been implicated in the genesis of muscle fatigue in muscular dystrophies. NO synthesized from L-arginine catalyzed by NO synthase is a widespread biological mediator with many functions, including cell signaling and protection from reactive oxygen intermediate superoxide. Loss of normal NO production in dystrophic muscle is expected to have a broad, disruptive effect on muscle function (9). Neuronal nitric oxide synthase (nNOS) is a key muscle enzyme in the production of NO, that is involved n the regulation of vasorelaxation and muscle blood supply. NOS is associated with dystrophin-associated protein complex at the sarcolemmal level, where it provides stability to the myofiber membrane during contraction. In the absence of dystrophin, as observed in dystrophinopathies, the concentration of NOS at the cell membrane and in the cytoplasm decreases, and the concentration of NOS mRNA is also reduced (10). It has been hypothesized, both in mdx mice and boys with Duchenne muscular dystrophy (11-13), that the displacement and the secondary loss of nNOS and abnormalities in the levels of its expression in muscle significantly contribute to fatigue by inducing muscle ischemia during contraction. Interestingly, nNOSnull mice display a specific deficit in adapting to exercise and develop profound fatigue upon repeated muscle contraction (14). nNOS levels were also reduced in other genetic forms of muscle disease, including those resulting from defects in extracellular matrix proteins laminin a2 and collagen VI. Mutations in dysferlin are also shown to be characterized by reduced levels of nNOS. Loss of the sarcoglycan–sarcospan complex in muscle, as observed in sarcoglicanopathies, causes a reduction in the levels of nNOS expression at the membrane, even in the presence of normal dystrophin expression (15).
Effects of exercise training in muscular dystrophies
In healthy individuals physical exercise training is considered one of best intervention to improve muscle strength, endurance and cardiorespiratory function. Regular exercise can also prevent diseases such as diabetes mellitus, arteriosclerosis, some forms of cancer, bone fractures, overweight, and it may improve cognition and mood. Moreover, it can avoid the age-related loss of muscle, called sarcopenia. Physical fitness training is a planned and structured regimen of regular physical exercise. In particular, strength training is defined as a training performed primarily to improve muscle strength and endurance and it is typically carried out making repeated muscle contractions against resistance. Indeed, aerobic exercise training, or cardiorespiratory fitness training, is a training that consists of an activity or combination of activities that uses large muscle groups, that can be continuously maintained, and that is rhythmical and aerobic, for example walking, running, cycling, or swimming (Fig. 1).
Studies of exercise training in patients with different neuromuscular diseases seem to suggest a positive effect without susceptibility to muscle injury (16- 18). In fact, strength training, which is performed to improve muscle strength and muscle endurance, or aerobic exercise programs, which involve training at moderate levels of intensity for extended periods of time (for example, distance cycling) might maximize muscle and cardiorespiratory function and prevent additional disuse atrophy (19). Previous studies demonstrated a beneficial effect of low- to moderate-intensity resistance and aerobic training in slowly progressive myopathies (20). An improvement in aerobic capacity may prevent type 2 diabetes, cardiovascular disease, and other lifestyle diseases. Patients with neuromuscular disorders are known to have a higher risk of developing disorders associated with obesity and a sedentary lifestyle, such as metabolic syndrome, when compared with the general population. Therefore, the positive effect of a training program on aerobic capacity in these patients is of substantial importance for their long-term health and quality of life (21, 22). However, clinicians are still afraid about muscle overuse during exercise in people with muscle disease and have a cautious approach to training. Limitations in patient number, design, and, most importantly, lack of supervision have often precluded any firm conclusion from previous studies (23). Importantly, as the pathophysiology of muscular dystrophies and myopathies differs, their reaction to training intervention might be different.
Muscle damage and exercise in LGMD
The damage of skeletal muscle during exercise may be caused by metabolic or mechanical mechanism. The metabolic damage is the result of ischemia or hypoxia during prolonged exercise, resulting in changes in ion concentration, accumulation of ROS and deficiency of ATP. Mechanical stimuli can determine muscle damage as direct consequence of overload of muscle fibers or inappropriate balance of exercise variables, with a secondary disruption of the sarcomeric Z lines (24) and plasma membrane with loss of muscle proteins, such as creatine kinase (CK), lactate dehydrogenase, aldolase, myoglobin, troponin.
Muscle contractions may determine mild and nosignificant damage of muscle fibers during daily common activities (25). More severe injuries accompanied by myalgias are also possible, especially during predominantly lengthening (eccentric) contractions. There are three different types of contractions. If the force developed by the muscle is greater than the load on the muscle, a shortening (concentric) contraction occurs. When the force developed by the muscle and the load are equivalent, or the load is immovable, a fixed length, or isometric contraction, results.
The third type of contraction occurs when the load on the muscle is greater than the force developed by the muscle and the muscle is stretched, producing a lengthening (eccentric) contraction. Depending on the severity of the injury, complete recovery may require from 7 to 30 days. Training with protocols of lengthening (eccentric) contractions produces a hypertrophic and stronger muscle. The "trained" muscle is then able to perform the protocol of repeated lengthening contractions that previously caused injury without sustaining an injury. It may be hypothesized that tear and load due to exercise on a sick muscle could accelerate the disease process in muscular dystrophies, in which sick fibres of different sizes, with disorganised myofibrillar structure, often undergoing regeneration or necrosis, in association with fibrosis and adipose tissue, does not seem for contractile activity. Based on the above considerations, patients with neuromuscular disorders in the past have been advised to refrain from strenuous exercise. But, one of the consequences of this is that patients develop severe deconditioning, with potential acceleration of the primary muscle disease process.
However, in last decade, a growing number of studies has shown that exercise can be safe and beneficial for several muscle diseases, but, to date, it is still unknown what kind of exercise (aerobic versus strength training) should be recommended, and at what duration, frequency and intensities it should be performed. Starting from actual knowledge, there is the need to plan future studies aimed at addressing if motor training for muscle disease can play a therapeutic effect (26).
Endurance training in LGMD2I (Sveen et al., 2007) (27)
Sveen and coworkers (27) analyzed the effect of lowintensity aerobic training in 9 patients with limb-girdle muscular dystrophy type 2I (LGMD2I), caused by mutation of fukutin-related protein, that is a cytosolic protein that glycosylates alpha-dystroglycan. Aplha-dystroglycan and integrin alpha-7beta-1D are the two main laminin receptors in skeletal muscle, playing a major role for the integrity of the sarcolemma. Exercise could be deleterious in patients with LGMD2I, considering the importance of alpha-dystroglycan in linking the sarcolemma to the extracellular matrix. The AA also evaluated the effect of a training program consisted in fifty 30-minute training sessions on cycle ergometer for 12 weeks, at a heart rate corresponding to 65% of their maximal oxygen uptake (VO2max). As a marker of exercise-inducing muscle damage, plasma CK was measured before and after a 12-week training period, 24 to 48 hours after the final training session. Plasma lactate and heart rate were used to validate the degree of exhaustion during cycle tests before and after training. Training improved VO2max and maximal workload in patients with LGMD2I. Plasma lactate levels and heart rate at rest and at VO2max did not differ significantly before and after training. Plasma CK levels tended to increase after training in patients, but also increased in nine matched healthy controls. Self-reported questionnaires showed that the majority of subjects with LGMD2I felt an improvement in physical endurance, leg muscle strength, and walking distance. No worsening of their condition or adverse events were reported.
The authors concluded that 12 weeks of low intensity aerobic training was effective and safe in increasing fitness in patients with LGMD2I. Training raised the patient's VO2max and workload capacity in watts by 21% and 27%, corresponding to the normal physiologic response to training in the healthy subjects. Increased work capacity was paralleled by self-reported improvements in endurance, leg muscle strength, and walking distance (27).
Resistance training in patients with LGMD2I and LGMD2A (Sveen et al., 2013) (28)
Sveen and coworkers presented the results of two pilot studies on the effect of resistance training in patients with LGMD2I, LGMD2A and Becker muscular dystrophy (BMD) (28). In particular, in one study they investigated the effect of low-intensity strength training (LOIT) in 2 patients with LGMD2A, in 4 patients with LGMD2I and 2 patients with BMD; in the other, they assessed the effect of high-intensity strength training (HIT) in 4 patients with LGMD2A, in 2 patients with LGMD2I and 1 patient with BMD. All recruited patients were ambulatory and considered to be mildly-moderately affected.
In LOIT study, the resistance-training program lasted 6 months. Two muscle groups were included in the training program: quadriceps (knee extension) and biceps brachii (elbow flexion). During the first 4 months of training the dominant side was trained, while both sides were trained for the final 2 months of training. The weight lifted during knee extension and elbow flexion started at 40% and was increased by 5% a week. Subjects were tested before and after 4 and 6 months of training for maximal strength and endurance (number of repetitions possible at 60% of maximal strenght). They also completed a questionnaire, named Sickness Impact Profile (SIP), for assessment of their daily function and quality of life. As a marker of exercise-induced muscle damage, plasma CK was monthly measured during the training period. At the end of the training period, elbow flexion and knee extension showed a significant increase in muscle strength and endurance; there was no change in the results from the SIP questionnaire regarding daily activities.
In HIT study, the training program lasted for 3 months. Additional muscle groups were included for testing, including wrist flexion and extension and plantar flexion, and both the right and left extremities were trained from the beginning. Subjects followed a strength training program with 3 sessions per week over the course of 12 weeks, with at least one day of rest between each training session. Supervision was provided during each session by a personal instructor. Patients were tested for maximum strength monthly. In order to measure endurance, patients performed as many repetitions as possible at 60% of their repeat maximun, which was found at the initial strength test. Each training session started with a 5-minute warm-up on a stationary cycle ergometer at low intensity, followed by three sets of each exercise performed with a 90-150-second interval between sets. In each set, the patient performed the maximum number of repetitions possible. Two patients with LGMD2A dropped out of the study because of training-induced CK elevations and myalgias. After 12 weeks of training, the strength of the patients improved in wrist flexion and extension, while the improvement in the other muscle groups was not significant. It was not observed a correlation between the initial strength level of the muscles and the percentage increase seen in the muscles. SIP questionnaire did not show changes in patient's self-reported daily status and quality of life.
In conclusion, the preliminary results of this work indicated that resistance training could be safe and effective in increasing muscle strength and endurance in muscular dystrophies with proximal weakness, such as LGMD. The authors highlighted, however, that, until more knowledge is convened, training should be carefully supervised in order to recognize potential adverse effects, particularly in high-intensity protocols (28).
Aerobic training in patients with LGMD2L (Vissing et al., 2014) (29)
LGMD2L is a recessively inherited dystrophy caused by mutations in ANO-5 gene, that encodes for the putative calcium-sensitive chloride channel anoctamin 5, which is thought to play a role in membrane repair. In this study, 6 ambulant patients with LGMD2L were selected in order to evaluate the effect of home-based, pulse-watch monitored, moderate-intensity exercise at home on a cycle ergometer for 30 minutes, 3 times weekly, for 10 weeks. Also in the present work, plasma CK was assessed as a marker of muscle damage. Training was performed at a heart rate interval corresponding to 70% of their VO2max. Primary outcome measures were VO2max and time in the 5-repetitions-sit-to-stand test (FRSTST), requiring patients to rise and sit from a chair 5 times as rapidly as possible. The authors reported a significant improvement in oxidative capacity and muscle function (evaluated by VO2max and FRSTST time), with stable CK levels and no reports of adverse effects (29).
Conclusions
In LGMD, because muscle weakness is the main problem, muscular exercise can help to counteract the loss of muscle tissue and strength in LGMD. Although it is accepted that exercise has a positive role in many diseases, it is not possible to generalize this finding to muscular dystrophy, including LGMD, and there is the need to conduct a systematic search to point out the effects of muscular exercise in experimental settings. To date, there is no certain evidences about the type (endurance or strength), frequency and intensity of muscle exercise. However, a training with moderate (below 70% of predicted maximal aerobic capacity) aerobic exercise seems to play an useful and safe effect in muscular dystrophies (23, 26).
Acknowledgements
We are thankful to all patients and their associations, in particular the "Unione Italiana Lotta alla Distrofia Muscolare, UILDM" (www.uildm.org) and the "Beta- Sarcoglicanopatie" Italian association (beta-sarcoglicanopatie. it). We wish to acknowledge the Italian Association of Myology (AIM), and Telethon Italy for its support GUP10006.
References
1. Allen DG. Skeletal muscle function: role of ionic changes in fatigue, damage and disease. Clin Exp Pharmacol Physiol. 2004;31:485–493. [PubMed]
2. Banerjee B, Sharma U, Balasubramanian K, et al. Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study. Magn Reson Imaging. 2010;28:698–707. [PubMed]
3. Tosetti M, Linsalata S, Battini R, et al. Muscle metabolic alterations assessed by 31-phosphorus magnetic resonance spectroscopy in mild Becker muscular dystrophy. Muscle Nerve. 2011;44:816–819. [PubMed]
4. Lodi R, Muntoni F, Taylor J, et al. Correlative MR imaging and 31P-MR spectroscopy study in sarcoglycan deficient limb girdle muscular dystrophy.Neuromuscul Disord. 1997;7:505–511. [PubMed]
5. Allen DG, Lamb GD, Westerblad H. Skeletal muscle fatigue: cellular mechanisms. Physiol Rev. 2008;88:287–332. [PubMed]
6. Reid MB. Free radicals and muscle fatigue: Of ROS, canaries, and the IOC.Free Radic Biol Med. 2008;44:169–179. [PubMed]
7. Ferreira LF, Reid MB. Muscle-derived ROS and thiol regulation in muscle fatigue. J Appl Physiol. 2008;104:853–860. (1985) [PubMed]
8. Kuwahara H, Horie T, Ishikawa S, et al. Oxidative stress in skeletal muscle causes severe disturbance of exercise activity without muscle atrophy. Free Radic Biol Med. 2010;48:1252–1262. [PubMed]
9. Tidball JG, Wehling-Henricks M. Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins. Mol Genet Metab.2004;82:312–320. [PubMed]
10. Wehling M1, Spencer MJ, Tidball JG. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol. 2001;155:123–131.[PMC free article] [PubMed]
11. Heydemann A, McNally E. NO more muscle fatigue. J Clin Invest.2009;119:448–450. [PMC free article] [PubMed]
12. Gücüyener K, Ergenekon E, Erbas D, et al. The serum nitric oxide levels in patients with Duchenne muscular dystrophy. Brain Dev. 2000;22:181–183.[PubMed]
13. Tidball JG, Wehling-Henricks M. Nitric oxide synthase deficiency and the pathophysiology of muscular dystrophy. J Physiol. 2014;592(Pt 21):4627–4638.[PMC free article] [PubMed]
14. Kobayashi YM, Rader EP, Crawford RW, et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature. 2008;456:511–515.[PMC free article] [PubMed]
15. Crosbie RH1, Barresi R, Campbell KP. Loss of sarcolemma nNOS in sarcoglycan-deficient muscle. FASEB J. 2002;16:1786–1791. [PubMed]
16. Vignos PJ, Watkins MP. The effect of exercise in muscular dystrophy. JAMA.1966;197:843–848. [PubMed]
17. McCartney N, Moroz D, Garner SH, et al. The effects of strength training in patients with selected neuromuscular disorders. Med Sci Sports Exerc.1988;20:362–368. [PubMed]
18. Aitkens SG, McCrory MA, Kilmer DD, et al. Moderate resistance exercise program: Its effect in slowly progressive neuromuscular disease. Arch Phys Med Rehabil. 1993;74:711–715. [PubMed]
19. Voet NB, Kooi EL, Riphagen, et al. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev. 2013;7:CD003907–CD003907. [PubMed]
20. Ansved T. Muscular dystrophies: influence of physical conditioning on the disease evolution. Curr Opin Clin Nutr Metab Care. 2003;6:435–439. [PubMed]
21. McCrory MA, Kim HR, Wright NC, et al. Energy expenditure, physical activity, and body composition of ambulatory adults with hereditary neuromuscular disease. Am J Clin Nutr. 1998;67:1162–1169. [PubMed]
22. Aitkens S, Kilmer DD, Wright NC, et al. Metabolic syndrome in neuromuscular disease. Arch Phys Med Rehabil. 2005;86:1030–1036. [PubMed]
23. Gianola S, Pecoraro V, Lambiase S, et al. Efficacy of muscle exercise in patients with muscular dystrophy: a systematic review showing a missed opportunity to improve outcomes. PLoS One. 2013;8:e65414–e65414.[PMC free article] [PubMed]
24. Luz CR, Nicastro H, Zanchi NE, et al. Potential therapeutic effects of branched-chain amino acids supplementation on resistance exercise-based muscle damage in humans. J Int Soc Sports Nutr. 2011;8:23–23. [PMC free article][PubMed]
25. Faulkner JA, Brooks SV, Opiteck JA. Conditions of Occurrence and Prevention: Injury to Skeletal Muscle Fibers During Contractions. Phys Ther.1993;73:911–921. [PubMed]
26. Vissing J, Engelen BG. 160th ENMC International Workshop (First ENMC practical care workshop) Exercise training in patients with muscle diseases: 20-22 June 2008, Naarden, The Netherlands. Neuromuscul Disord. 2013;23:182–187.[PubMed]
27. Sveen ML, Jeppesen TD, Hauerslev S, et al. Endurance training: An effective and safe treatment for patients with LGMD2I. Neurology. 2007;68:59–61.[PubMed]
28. Sveen ML, Andersen SP, Ingelsrud LH, et al. Resistance training in patients with limb-girdle and becker muscular dystrophies. Muscle Nerve. 2013;47:163–169. [PubMed]
29. Vissing CR, Preisler N, Husu E, et al. Aerobic training in patients with anoctamin 5 myopathy and hyperckemia. Muscle Nerve. 2014;50:119–123.[PubMed]
Articles from Acta Myologica are provided here courtesy of Pacini Editore
Monday 13 July 2015
Friday 10 July 2015
Muscular Dystrophy Heavily Affecting US Latino Males By Nicole Akoukou Thompson (staff@latinpost.com)
Duchenne/Becker (DBMD) and Facioscapulohumeral muscular dystrophies are a part of a group of more than 30 genetic diseases that cause progressive weakness and loss of muscular mass. Recent reports show that prevalence of muscular dystrophy is higher among Hispanic individuals than non-Hispanic white or black individuals. However, there have been a series of research developments that could lead to future therapies for the currently untreatable disease.
The genetic muscle-weakening disorder DBMD affects 1 in 5,600 to 7,700 males (5 through 24 years of age) in the United States, and a recently published report, printed in the journal "Pediatrics," revealed that prevalence rates for DBMD is highest among Latinos.
DBMD primarily affect boys (between ages 7 and 13), robbing them of their ability to walk and lead to an early death. While the reported documented more cases of MD among non-Hispanic whites (reflecting the sizable proportion of non-Hispanic white individuals in the MD STARnet), it showed that prevalence rates were highest among Hispanics (1.50 per 10,000 compared to 1.45 per 10,000 for non-Hispanic white).
The identification of the novel gene, Smchd1, has exposed the gene's involvement in the development of facioscapulohumeral muscular dystrophy. Researchers at the Walter and Eliza Hall Institute in Australia piloted research that established that Smchd1 is involved in DNA management and X chromosome inactivation. According to the report, the gene is dysfunctional in patients with FSHD2, a rare form of facioscapulohumeral muscular dystrophy (FSHD), which is a disorder that affects the skeletal muscles of the face, shoulders and upper arms.
Smchd1 is very unusual in its interactions with the genome and encodes an epigenetic factor that can switch genes off to suppress their function. The 'Goliath' molecule "very delicately squeezes itself into a tiny 'seat' on the DNA. It binds at just a few discrete sites on the DNA, and then draws these pieces together to 'shield' them from being activated," said researchers from Walter and Eliza Hall Institute.
The critical discovery of the gene allows for the deeper research into genetic changes, mutation and its effect on functions. In the long term, Smchd1 researchers could develop drugs that act as a substitute during mutation activity and prevents debilitating muscle wasting.
To revisit the subject of developing a drug to treat muscular dystrophy, a pioneering treatment has been developed to eliminate the severe muscle-wasting condition known as Duchenne muscular dystrophy. However, the drug has been turned down for early NHS funding.
European Medicines Agency (EMA) approved Translarna during August 2014, and it became the first drug to address the cause of Duchenne muscular dystrophy, which is a progressive genetic disorder characterized by muscle erosion and weakness, is caused by an absence of dystrophin, a protein that helps to keep muscle cells intact. While Translarna is available in many EU nations, it isn't available in England and several other nations around the world. The drug could help to slow muscle progression and help children to walk longer.
Following NHS England's rejection, the National Institute for Health and Care Excellence (NICE) plans to conduct a drug review on Translarna, and they will report back in early 2016. During December 2014, Translarna was granted orphan drug designation (ODD) status in the U.S. and Europe for the Treatment of mucopolysaccharidosis.
"It is very disappointing for the Duchenne muscular dystrophy community that the NHS has decided not to fund Translarna at this juncture. The drug is already available in several European countries following EMA conditional approval last year including Germany, Greece, Italy and France," said professor Kate Bushby from the The John Walton Muscular Dystrophy Research Centre and lead for that clinical trial of Translarna Drugs, in a recent news release. "Drugs for rare diseases are very expensive, but this is a function of the development pipeline and should not disadvantage the patients who suffer from these conditions.
"If we are to have a constructive pipeline for rare disease drug development, then there needs to be a way to ensure that drugs which have been approved by the EMA have a mechanism to be available on the NHS."
Bushby continued to state that it was disheartening to see investments from the research community and time from patients and families go to waste after they've participated in studies.
Robert Meadowcroft, chief executive of Muscular Dystrophy U.K., said in a news release, "This news is a harsh blow to each and every boy and young man living with Duchenne muscular dystrophy. ... Parents of young children have faced a grueling nine-month wait for an answer on funding, only to hear 'no' from NHS England. ... Our focus now is to support parents affected by this decision through the waiting period, and to explore all alternatives, including working with senior doctors on requests for individual funding."
When it comes to the prevalence of Duchenne and muscular dystrophy in the U.S., rates are highest for Hispanic individuals and lowest for non-Hispanic black individuals. Also, concerning estimates for disease development in relation to age, Hispanic individuals exceeded non-Hispanic white individuals for all but the youngest age group. Additionally, when prevalence rates managed to decrease, rates for Latinos still exceed rates for other racial and ethnic groups.
Researchers are unclear as to why Latino males are heavily impacted by the disease, but the new study could heighten awareness about disease prevalence and understanding about the role the disease can play in the lives of young men.
The genetic muscle-weakening disorder DBMD affects 1 in 5,600 to 7,700 males (5 through 24 years of age) in the United States, and a recently published report, printed in the journal "Pediatrics," revealed that prevalence rates for DBMD is highest among Latinos.
DBMD primarily affect boys (between ages 7 and 13), robbing them of their ability to walk and lead to an early death. While the reported documented more cases of MD among non-Hispanic whites (reflecting the sizable proportion of non-Hispanic white individuals in the MD STARnet), it showed that prevalence rates were highest among Hispanics (1.50 per 10,000 compared to 1.45 per 10,000 for non-Hispanic white).
The identification of the novel gene, Smchd1, has exposed the gene's involvement in the development of facioscapulohumeral muscular dystrophy. Researchers at the Walter and Eliza Hall Institute in Australia piloted research that established that Smchd1 is involved in DNA management and X chromosome inactivation. According to the report, the gene is dysfunctional in patients with FSHD2, a rare form of facioscapulohumeral muscular dystrophy (FSHD), which is a disorder that affects the skeletal muscles of the face, shoulders and upper arms.
Smchd1 is very unusual in its interactions with the genome and encodes an epigenetic factor that can switch genes off to suppress their function. The 'Goliath' molecule "very delicately squeezes itself into a tiny 'seat' on the DNA. It binds at just a few discrete sites on the DNA, and then draws these pieces together to 'shield' them from being activated," said researchers from Walter and Eliza Hall Institute.
The critical discovery of the gene allows for the deeper research into genetic changes, mutation and its effect on functions. In the long term, Smchd1 researchers could develop drugs that act as a substitute during mutation activity and prevents debilitating muscle wasting.
To revisit the subject of developing a drug to treat muscular dystrophy, a pioneering treatment has been developed to eliminate the severe muscle-wasting condition known as Duchenne muscular dystrophy. However, the drug has been turned down for early NHS funding.
European Medicines Agency (EMA) approved Translarna during August 2014, and it became the first drug to address the cause of Duchenne muscular dystrophy, which is a progressive genetic disorder characterized by muscle erosion and weakness, is caused by an absence of dystrophin, a protein that helps to keep muscle cells intact. While Translarna is available in many EU nations, it isn't available in England and several other nations around the world. The drug could help to slow muscle progression and help children to walk longer.
Following NHS England's rejection, the National Institute for Health and Care Excellence (NICE) plans to conduct a drug review on Translarna, and they will report back in early 2016. During December 2014, Translarna was granted orphan drug designation (ODD) status in the U.S. and Europe for the Treatment of mucopolysaccharidosis.
"It is very disappointing for the Duchenne muscular dystrophy community that the NHS has decided not to fund Translarna at this juncture. The drug is already available in several European countries following EMA conditional approval last year including Germany, Greece, Italy and France," said professor Kate Bushby from the The John Walton Muscular Dystrophy Research Centre and lead for that clinical trial of Translarna Drugs, in a recent news release. "Drugs for rare diseases are very expensive, but this is a function of the development pipeline and should not disadvantage the patients who suffer from these conditions.
"If we are to have a constructive pipeline for rare disease drug development, then there needs to be a way to ensure that drugs which have been approved by the EMA have a mechanism to be available on the NHS."
Bushby continued to state that it was disheartening to see investments from the research community and time from patients and families go to waste after they've participated in studies.
Robert Meadowcroft, chief executive of Muscular Dystrophy U.K., said in a news release, "This news is a harsh blow to each and every boy and young man living with Duchenne muscular dystrophy. ... Parents of young children have faced a grueling nine-month wait for an answer on funding, only to hear 'no' from NHS England. ... Our focus now is to support parents affected by this decision through the waiting period, and to explore all alternatives, including working with senior doctors on requests for individual funding."
When it comes to the prevalence of Duchenne and muscular dystrophy in the U.S., rates are highest for Hispanic individuals and lowest for non-Hispanic black individuals. Also, concerning estimates for disease development in relation to age, Hispanic individuals exceeded non-Hispanic white individuals for all but the youngest age group. Additionally, when prevalence rates managed to decrease, rates for Latinos still exceed rates for other racial and ethnic groups.
Researchers are unclear as to why Latino males are heavily impacted by the disease, but the new study could heighten awareness about disease prevalence and understanding about the role the disease can play in the lives of young men.
Thursday 9 July 2015
12 Things Not to Say to Someone Who Has a Chronic Illness by Tess Koman
This statements have been told to people with muscular dystrophy ''they look fine'' several times...
1. "At least it's not cancer."
You're right! Every day I am so insanely grateful that it's not [X horrible disease], but that doesn't mean I want to be reminded of it. I feel terrible that other people have it worse than I do, but it actually helps me to mope a little bit about how badly I've got it some days. I'm allowed to mope no matter how big my problems are comparatively.
2. "Oh, yeah, I get terrible cramps/pains/aches too."
Girl, I'm sure you do. And I am not taking away from whatever miserable thing happens when you get your period because periods suuuck. That being said, I don't really want to compare your cramps or whatever to something that's sent me to the hospital a few times.
1. "At least it's not cancer."
You're right! Every day I am so insanely grateful that it's not [X horrible disease], but that doesn't mean I want to be reminded of it. I feel terrible that other people have it worse than I do, but it actually helps me to mope a little bit about how badly I've got it some days. I'm allowed to mope no matter how big my problems are comparatively.
2. "Oh, yeah, I get terrible cramps/pains/aches too."
Girl, I'm sure you do. And I am not taking away from whatever miserable thing happens when you get your period because periods suuuck. That being said, I don't really want to compare your cramps or whatever to something that's sent me to the hospital a few times.
3. "You have to get your stress under control."
Totally. I totally do! There is absolutely a connection between mental health and physical health, and I am constantly reminded of this when I manage to actually make myself sick. Thank you though for adding to my stresses about being stressed.
Totally. I totally do! There is absolutely a connection between mental health and physical health, and I am constantly reminded of this when I manage to actually make myself sick. Thank you though for adding to my stresses about being stressed.
4. "But you look OK!"
It takes a lot of time and effort for me to look OK some days. What you're looking at is a fully medicated, sometimes self-conscious, totally-prepared-in-case-of-disaster human who doesn't want you looking at her like she is nothing more than her disease. I'm happy to hear you judge a book by its cover though!
5. "Have you tried X drug? Or Y drug?"
I truly appreciate your concern (and curiosity! I never mind if you ask respectful questions.) and I know you WebMD'ed my illness after the last time we spoke because you care. That being said, I tried that drug (and that other drug. And probably, like, seven other drugs) a few years ago at the suggestion of my doctor ... who has an M.D.
It takes a lot of time and effort for me to look OK some days. What you're looking at is a fully medicated, sometimes self-conscious, totally-prepared-in-case-of-disaster human who doesn't want you looking at her like she is nothing more than her disease. I'm happy to hear you judge a book by its cover though!
5. "Have you tried X drug? Or Y drug?"
I truly appreciate your concern (and curiosity! I never mind if you ask respectful questions.) and I know you WebMD'ed my illness after the last time we spoke because you care. That being said, I tried that drug (and that other drug. And probably, like, seven other drugs) a few years ago at the suggestion of my doctor ... who has an M.D.
6. "My cousin's friend's sister has that and it's not so bad."
The weird thing about bodies is that they're all different. Your immune system is different than my immune system and my problems are different than your cousin's friend's sister's problems.
The weird thing about bodies is that they're all different. Your immune system is different than my immune system and my problems are different than your cousin's friend's sister's problems.
7. "Did you try going gluten-free? My cousin's friend's sister went gluten-free and it solved all her problems."
Going gluten-free solves problems for people who have celiac disease or gluten intolerances. Again, I'm super happy that you cousin's friend's sister is doing really well (Seriously!) but you're killing me, smalls.
8. "Wow, you're so young to be dealing with that."
Yep. See no. 1.
9. "Weren't you just at the doctor?"
"Chronic" means recurring. Dealing with chronic illnesses means dealing with recurring symptoms that require constant monitoring and treatment. I don't leave work every other week for fun — I do it for my health. It's really important that I stay on top of my doctor's visits.
Going gluten-free solves problems for people who have celiac disease or gluten intolerances. Again, I'm super happy that you cousin's friend's sister is doing really well (Seriously!) but you're killing me, smalls.
8. "Wow, you're so young to be dealing with that."
Yep. See no. 1.
9. "Weren't you just at the doctor?"
"Chronic" means recurring. Dealing with chronic illnesses means dealing with recurring symptoms that require constant monitoring and treatment. I don't leave work every other week for fun — I do it for my health. It's really important that I stay on top of my doctor's visits.
10. "Is it fatal? Will you die?"
I can't speak for everyone, but I vividly remember my doctor telling my panicked mom that my disease was "completely life-altering, but not life-ending" upon my diagnosis. I was 7 and that line has worked for me in the face of this question ever since.
11. "Oh, cool, I saw an episode of House on that once!"
Cool! Did the episode end well? Or did the person die? I ask because one time I saw that same episode of House and it did not end well, so I texted my doctor frantically — yeah, I text my doctor, come at me, bro — who told me that TV is dumb sometimes.
12. "Oh ... that's gross."
Love that you called my existence gross. Love! Thanks!
via: http://www.cosmopolitan.com/lifestyle/news/a42927/things-not-to-say-to-someone-who-has-a-chronic-illness/
I can't speak for everyone, but I vividly remember my doctor telling my panicked mom that my disease was "completely life-altering, but not life-ending" upon my diagnosis. I was 7 and that line has worked for me in the face of this question ever since.
11. "Oh, cool, I saw an episode of House on that once!"
Cool! Did the episode end well? Or did the person die? I ask because one time I saw that same episode of House and it did not end well, so I texted my doctor frantically — yeah, I text my doctor, come at me, bro — who told me that TV is dumb sometimes.
12. "Oh ... that's gross."
Love that you called my existence gross. Love! Thanks!
via: http://www.cosmopolitan.com/lifestyle/news/a42927/things-not-to-say-to-someone-who-has-a-chronic-illness/
Saturday 4 July 2015
For Nairobi's Disabled, an Equal Chance Behind the Wheel by Lenny Ruvaga
NAIROBI—
Each day, 45-year-old George Papai makes an arduous journey to and from work — and his commute is unusually long.
Today is no different. Whereas an able-bodied person would make the same bus trip in about 45 minutes, it takes Papai two hours.
In a country whose infrastructure, buildings and transit policies fail to factor in needs of the disabled, Papai and others like him feel like second-class citizens.
“The way the buildings [used to be] constructed, they are not disabled-friendly," he said. "Even the cars — most of them they are not disabled-friendly. Some people have wheelchairs [and] they find it a problem to get into the vehicle with their wheelchair, and they don’t even have space to place their wheelchairs.”
Carlos Lwangu, who manages a fleet of 11 buses that shuttle between Nairobi and Ngong, disabled citizens need help from both the public and private sector.
“If the government looked into it, and even if the private sector looked at the situation as well, we would look at the paraplegics, pregnant women and the children," he said. "All this [would] make the community better so that public transport will be sufficient for all these three groups."
This kind of built-in inequality is what one Nairobi-based driving school is hoping to address by offering driving lessons for the disabled.
Nearly 10 years ago, Rocky Driving School instructors began teaching physically impaired students the skills essential to operating specially-equipped cars.
They are the only driving school in East and Central Africa to offer the special courses.
Dismas Ondoro, one of the specially-trained instructors, says the training vehicles, which cost about $1,000 to modify, have a lever attached to both the accelerator and brake pedals. When students want to accelerate, they push the lever forward. When they want to brake, they push it back. Ondoro says the lever can be used by people with any number of handicaps.
For Papai, who is currently enrolled in one of the $150 driving courses, which take four weeks to complete, the experience has the potential dramatically expand horizons of independence and personal mobility.
“I am very much excited at learning how to drive, because by so doing I can also drive like any other [able-bodied] person, unlike before where we felt we have been left out or we cannot be able to drive on our own," he said.
With only five more lessons to go before he takes the National driving exam, Papai is confident that at last he will be behind the wheel of his own destiny.
via http://www.voanews.com/content/nairobi-disabled-driving-school-handicap-transit-kenya/2412030.html
Subscribe to:
Posts (Atom)